8-K Announcements
6Material company update
Feb 12, 2026·SEC
Material company update
Jan 20, 2026·SEC
Material company update
Jan 12, 2026·SEC
Avadel Pharmaceuticals has successfully transitioned into a commercial-stage entity, evidenced by a 54.9% quarterly revenue growth rate as of 2025Q3 and the achievement of positive operating margins. While the company's proprietary delivery technology supports...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest Mar 2, 2026 | -$0.05-162.5% vs $0.08 | — vs $80M |
Q4 2025 Nov 4, 2025 | — vs $0.04 | $77M-3.5% vs $80M |
Q3 2025 Aug 7, 2025 | $0.10+400.0% vs $0.02 | $68M-7.4% vs $74M |
Q2 2025 May 7, 2025 | -$0.05+28.6% vs -$0.07 | $53M-9.8% vs $58M |
Benchmark AVDL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Avadel Pharmaceuticals plc (AVDL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $21.64 | $2.1B | -42.43 | 504.79% | -28.87% | -60.44% | — | |
| $234.88 | $14.75B | -40.22 | 4.88% | 20.45% | 21.37% | — | |
| $193.45 | $9.95B | -52.57 | 65.55% | -24.68% | -255.6% | — | |
| $20.24 | $1.49B | 6.13 | 18.52% | 80.56% | 30.03% | — | |
| $43.39 | $2.52B | -63.81 | 8.63% | -13.23% | -10.42% | — | |
| $25.83 | $2.02B | 39.74 | 10.4% | 6% | 15.98% | — |
Avadel Pharmaceuticals plc (AVDL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Avadel Pharmaceuticals plc (AVDL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Feb 12, 2026·SEC
Jan 20, 2026·SEC
Jan 12, 2026·SEC
Get notified when AVDL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Avadel Pharmaceuticals plc (AVDL) stock FAQ — growth, dividends, profitability & financials explained
Avadel Pharmaceuticals plc (AVDL) reported $248.5M in revenue for fiscal year 2024. This represents a 4972% increase from $4.9M in 1996.
Avadel Pharmaceuticals plc (AVDL) grew revenue by 504.8% over the past year. This is strong growth.
Avadel Pharmaceuticals plc (AVDL) reported a net loss of $0.3M for fiscal year 2024.
Avadel Pharmaceuticals plc (AVDL) has a return on equity (ROE) of -60.4%. Negative ROE indicates the company is unprofitable.
Avadel Pharmaceuticals plc (AVDL) generated $35.4M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.